Radiotherapy for inferior vena cava tumor thrombus in patients with hepatocellular carcinoma

BMC Cancer

Table 2 Treatment Characteristics

Treatment	No. of patients (%)
Previous treatment^a
None	15 (35.7)
Operation	10 (23.8)
TACE/TAE	19 (45.2)
RFA/PEI	11 (26.2)
Systemic treatment	12 (28.6)
Treatment concurrent with RT^b
None	13 (31.0)
Operation	0 (0.0)
TACE/TAE	12 (28.6)
RFA/PEI	1 (2.4)
Systemic treatment	24 (57.1)
Treatment after RT^c
None	20 (47.6)
Operation	4 (9.5)
TACE/TAE	6 (14.3)
RFA/PEI	1 (2.4)
Systemic treatment	21 (50.0)
RT technique
3DCRT	7 (16.7)
IMRT	35 (83.3)
RT dose (EQD_10/2, Gy)^d
Median (range)	48.75 (3.25–67.10)
< 50	22 (52.4)
≥ 50	20 (47.6)

Abbreviations: RT radiotherapy, TACE transarterial chemoembolization, TAE transarterial embolization, RFA radiofrequency ablation, PEI percutaneous ethanol injection, 3DCRT three-dimensional conformal radiotherapy, IMRT intensity modulation radiation therapy
^aTreatment given beyond 4 weeks before RT began
^bTreatment given within 4 weeks before RT began or 4 weeks after RT completed
^cTreatment given beyond 4 weeks after RT completed
^dEquivalent dose in 2 Gy fractions, α/β = 10

ISSN: 1471-2407